Loading…
A response to the opioid overdose epidemic: naloxone nasal spray
Opioid overdose morbidity and mortality is recognized to have epidemic proportions. Medical and public health agencies are adopting opioid harm reduction strategies to reduce the morbidity and mortality associated with overdose. One strategy developed by emergency medical services and public health...
Saved in:
Published in: | Drug delivery and translational research 2013-02, Vol.3 (1), p.63-74 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c442t-518b89f6e57435268185bfd0fd9bb91b7bec2e93addc59709271ead2145a356a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c442t-518b89f6e57435268185bfd0fd9bb91b7bec2e93addc59709271ead2145a356a3 |
container_end_page | 74 |
container_issue | 1 |
container_start_page | 63 |
container_title | Drug delivery and translational research |
container_volume | 3 |
creator | Wermeling, Daniel P. |
description | Opioid overdose morbidity and mortality is recognized to have epidemic proportions. Medical and public health agencies are adopting opioid harm reduction strategies to reduce the morbidity and mortality associated with overdose. One strategy developed by emergency medical services and public health agencies is to deliver the opioid antidote naloxone injection intranasally to reverse the effects of opioids. Paramedics have used this route to quickly administer naloxone in a needle-free system and avoiding needlestick injuries and contracting a blood-born pathogen disease such as hepatitis or human immunodeficiency virus. Public health officials advocate broader lay person access since civilians are likely witnesses or first responders to an opioid overdose in a time-acute setting. The barrier to greater use of naloxone is that a suitable and optimized needle-free drug delivery system is unavailable. The scientific basis for design and study of an intranasal naloxone product is described. Lessons from nasal delivery of opioid analgesics are applied to the consideration of naloxone nasal spray. |
doi_str_mv | 10.1007/s13346-012-0092-0 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3668569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1665117285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-518b89f6e57435268185bfd0fd9bb91b7bec2e93addc59709271ead2145a356a3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMoKuoP8CI9eqnmO40HURa_QPCi4C2kzXQ30m1q0l3cf29kddGLc8gMmXfeZB6Ejgk-Ixir80QY47LEhJYY63xsoX1KNC6Z5tX2pmave-gopTecg0uitNpFe5Qpxhmn--jquoiQhtAnKMZQjDMowuCDd0VYQnQhX8PgHcx9c1H0tgsfoYdcJNsVaYh2dYh2WtslOPrOB-jl9uZ5cl8-Pt09TK4fy4ZzOpaCVHWlWwlCcSaorEgl6tbh1um61qRWNTQUNLPONUKrvJAiYB0lXFgmpGUH6HLtOyzqObgG-jHazgzRz21cmWC9-dvp_cxMw9IwKSshdTY4_TaI4X0BaTRznxroOttDWCRDpBSEKFqJLCVraRNDShHazTMEmy_4Zg3fZPjmC77Beebk9_82Ez-os4CuBRmb76cQzVtYxIw0_eP6Cdfjj9Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1665117285</pqid></control><display><type>article</type><title>A response to the opioid overdose epidemic: naloxone nasal spray</title><source>Springer Nature</source><creator>Wermeling, Daniel P.</creator><creatorcontrib>Wermeling, Daniel P.</creatorcontrib><description>Opioid overdose morbidity and mortality is recognized to have epidemic proportions. Medical and public health agencies are adopting opioid harm reduction strategies to reduce the morbidity and mortality associated with overdose. One strategy developed by emergency medical services and public health agencies is to deliver the opioid antidote naloxone injection intranasally to reverse the effects of opioids. Paramedics have used this route to quickly administer naloxone in a needle-free system and avoiding needlestick injuries and contracting a blood-born pathogen disease such as hepatitis or human immunodeficiency virus. Public health officials advocate broader lay person access since civilians are likely witnesses or first responders to an opioid overdose in a time-acute setting. The barrier to greater use of naloxone is that a suitable and optimized needle-free drug delivery system is unavailable. The scientific basis for design and study of an intranasal naloxone product is described. Lessons from nasal delivery of opioid analgesics are applied to the consideration of naloxone nasal spray.</description><identifier>ISSN: 2190-393X</identifier><identifier>EISSN: 2190-3948</identifier><identifier>DOI: 10.1007/s13346-012-0092-0</identifier><identifier>PMID: 23734342</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Pharmaceutical Sciences/Technology ; Review Article</subject><ispartof>Drug delivery and translational research, 2013-02, Vol.3 (1), p.63-74</ispartof><rights>Controlled Release Society 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-518b89f6e57435268185bfd0fd9bb91b7bec2e93addc59709271ead2145a356a3</citedby><cites>FETCH-LOGICAL-c442t-518b89f6e57435268185bfd0fd9bb91b7bec2e93addc59709271ead2145a356a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23734342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wermeling, Daniel P.</creatorcontrib><title>A response to the opioid overdose epidemic: naloxone nasal spray</title><title>Drug delivery and translational research</title><addtitle>Drug Deliv. and Transl. Res</addtitle><addtitle>Drug Deliv Transl Res</addtitle><description>Opioid overdose morbidity and mortality is recognized to have epidemic proportions. Medical and public health agencies are adopting opioid harm reduction strategies to reduce the morbidity and mortality associated with overdose. One strategy developed by emergency medical services and public health agencies is to deliver the opioid antidote naloxone injection intranasally to reverse the effects of opioids. Paramedics have used this route to quickly administer naloxone in a needle-free system and avoiding needlestick injuries and contracting a blood-born pathogen disease such as hepatitis or human immunodeficiency virus. Public health officials advocate broader lay person access since civilians are likely witnesses or first responders to an opioid overdose in a time-acute setting. The barrier to greater use of naloxone is that a suitable and optimized needle-free drug delivery system is unavailable. The scientific basis for design and study of an intranasal naloxone product is described. Lessons from nasal delivery of opioid analgesics are applied to the consideration of naloxone nasal spray.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Review Article</subject><issn>2190-393X</issn><issn>2190-3948</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMoKuoP8CI9eqnmO40HURa_QPCi4C2kzXQ30m1q0l3cf29kddGLc8gMmXfeZB6Ejgk-Ixir80QY47LEhJYY63xsoX1KNC6Z5tX2pmave-gopTecg0uitNpFe5Qpxhmn--jquoiQhtAnKMZQjDMowuCDd0VYQnQhX8PgHcx9c1H0tgsfoYdcJNsVaYh2dYh2WtslOPrOB-jl9uZ5cl8-Pt09TK4fy4ZzOpaCVHWlWwlCcSaorEgl6tbh1um61qRWNTQUNLPONUKrvJAiYB0lXFgmpGUH6HLtOyzqObgG-jHazgzRz21cmWC9-dvp_cxMw9IwKSshdTY4_TaI4X0BaTRznxroOttDWCRDpBSEKFqJLCVraRNDShHazTMEmy_4Zg3fZPjmC77Beebk9_82Ez-os4CuBRmb76cQzVtYxIw0_eP6Cdfjj9Q</recordid><startdate>20130201</startdate><enddate>20130201</enddate><creator>Wermeling, Daniel P.</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130201</creationdate><title>A response to the opioid overdose epidemic: naloxone nasal spray</title><author>Wermeling, Daniel P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-518b89f6e57435268185bfd0fd9bb91b7bec2e93addc59709271ead2145a356a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wermeling, Daniel P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug delivery and translational research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wermeling, Daniel P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A response to the opioid overdose epidemic: naloxone nasal spray</atitle><jtitle>Drug delivery and translational research</jtitle><stitle>Drug Deliv. and Transl. Res</stitle><addtitle>Drug Deliv Transl Res</addtitle><date>2013-02-01</date><risdate>2013</risdate><volume>3</volume><issue>1</issue><spage>63</spage><epage>74</epage><pages>63-74</pages><issn>2190-393X</issn><eissn>2190-3948</eissn><abstract>Opioid overdose morbidity and mortality is recognized to have epidemic proportions. Medical and public health agencies are adopting opioid harm reduction strategies to reduce the morbidity and mortality associated with overdose. One strategy developed by emergency medical services and public health agencies is to deliver the opioid antidote naloxone injection intranasally to reverse the effects of opioids. Paramedics have used this route to quickly administer naloxone in a needle-free system and avoiding needlestick injuries and contracting a blood-born pathogen disease such as hepatitis or human immunodeficiency virus. Public health officials advocate broader lay person access since civilians are likely witnesses or first responders to an opioid overdose in a time-acute setting. The barrier to greater use of naloxone is that a suitable and optimized needle-free drug delivery system is unavailable. The scientific basis for design and study of an intranasal naloxone product is described. Lessons from nasal delivery of opioid analgesics are applied to the consideration of naloxone nasal spray.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23734342</pmid><doi>10.1007/s13346-012-0092-0</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2190-393X |
ispartof | Drug delivery and translational research, 2013-02, Vol.3 (1), p.63-74 |
issn | 2190-393X 2190-3948 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3668569 |
source | Springer Nature |
subjects | Biomedical and Life Sciences Biomedicine Pharmaceutical Sciences/Technology Review Article |
title | A response to the opioid overdose epidemic: naloxone nasal spray |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A56%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20response%20to%20the%20opioid%20overdose%20epidemic:%20naloxone%20nasal%20spray&rft.jtitle=Drug%20delivery%20and%20translational%20research&rft.au=Wermeling,%20Daniel%20P.&rft.date=2013-02-01&rft.volume=3&rft.issue=1&rft.spage=63&rft.epage=74&rft.pages=63-74&rft.issn=2190-393X&rft.eissn=2190-3948&rft_id=info:doi/10.1007/s13346-012-0092-0&rft_dat=%3Cproquest_pubme%3E1665117285%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c442t-518b89f6e57435268185bfd0fd9bb91b7bec2e93addc59709271ead2145a356a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1665117285&rft_id=info:pmid/23734342&rfr_iscdi=true |